GA
AXDX

Geneva Advisors’s Accelerate Diagnostics AXDX Stock Holding History

Geneva Advisors’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$1.34M Buy
4,890
+24
+0.5% +$6.5K 0.02% 306
2017
Q1 		$1.18M Buy
4,866
+211
+5% +$48.2K 0.02% 317
2016
Q4 		$966K Buy
4,655
+194
+4% +$46.1K 0.02% 349
2016
Q3 		$1.22M Buy
4,461
+1,743
+64% +$386K 0.02% 278
2016
Q2 		$391K Buy
2,718
+93
+4% +$12.5K 0.01% 499
2016
Q1 		$377K Buy
2,625
+100
+4% +$14.1K 0.01% 493
2015
Q4 		$543K Buy
2,525
+587
+30% +$107K 0.01% 402
2015
Q3 		$314K Hold
1,938
– – 0.01% 474
2015
Q2 		$500K Hold
1,938
– – 0.01% 429
2015
Q1 		$436K Hold
1,938
– – 0.01% 439
2014
Q4 		$372K Buy
1,938
+168
+9% +$36K 0.01% 471
2014
Q3 		$380K Buy
1,770
+200
+13% +$38.9K 0.01% 472
2014
Q2 		$408K Buy
1,570
+192
+14% +$41.9K 0.01% 463
2014
Q1 		$300K Hold
1,378
– – 0.01% 480
2013
Q4 		$168K Buy
+1,378
New +$184K ﹤0.01% 475

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Geneva Advisors's AXDX Position: Q2 2017 in Review

Geneva Advisors increased its Accelerate Diagnostics (AXDX) stake by 0.49% in Q2 2017, buying an estimated $6.5K and bringing the position to 4,890 shares worth $1.34M. The position accounts for 0.02% of the portfolio, ranked #306.

Geneva Advisors first reported a position in AXDX in Q4 2013 and has held it in 15 quarters since. 119 funds tracked by Wall St. Rank hold AXDX as of Q2 2017.

  • Geneva Advisors held 4,890 shares of Accelerate Diagnostics worth $1.34M as of Q2 2017.
  • Geneva Advisors bought 24 Accelerate Diagnostics shares in Q2 2017, an estimated $6.5K.
  • Accelerate Diagnostics made up 0.02% of Geneva Advisors's portfolio in Q2 2017, its #306 holding.
  • Geneva Advisors first reported a position in Accelerate Diagnostics in Q4 2013 and has held it in 15 quarters since.
  • 119 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.